Risperidone plasma levels, clinical response and side–effects

[1]  H. Möller.  Management of the Negative Symptoms of Schizophrenia , 2012, CNS drugs.

[2]  K. Nuechterlein,et al.  Intra- and Interindividual Variations in Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Schizophrenic Patients Treated Chronically with Various Doses of Risperidone , 2003, Therapeutic drug monitoring.

[3]  A. Zackrisson,et al.  Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing , 2003, European Journal of Clinical Pharmacology.

[4]  G. Baker,et al.  Interactions between the cytochrome P450 system and the second-generation antipsychotics. , 2003, Journal of psychiatry & neuroscience : JPN.

[5]  T. Iga,et al.  Effects of CYP2D6 Genotypes on Plasma Concentrations of Risperidone and Enantiomers of 9‐Hydroxyrisperidone in Japanese Patients with Schizophrenia , 2003, Journal of clinical pharmacology.

[6]  J. Gomez,et al.  Relationship between Risperidone and 9-hydroxy-risperidone Plasma Concentrations and CYP2D6 Enzyme Activity in Psychiatric Patients , 2002, Pharmacopsychiatry.

[7]  J. Markowitz,et al.  In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. , 2002, Life sciences.

[8]  S. Marder,et al.  Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats , 2002, Psychopharmacology.

[9]  H. Nasrallah,et al.  Iatrogenic Disorders Associated with Conventional vs. Atypical Antipsychotics , 2001, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[10]  L. Bertilsson,et al.  Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients , 2001, European Journal of Clinical Pharmacology.

[11]  R. Yoshimura,et al.  Possible Relationship between Combined Plasma Concentrations of Risperidone plus 9-Hydroxyrisperidone and Extrapyramidal Symptoms , 2001, Neuropsychobiology.

[12]  M. Luyckx,et al.  Risperidone Drug Monitoring , 2000 .

[13]  T. Sunderland,et al.  Geriatric Psychopharmacology: Why Does Age Matter? , 2000, Harvard review of psychiatry.

[14]  H. Möller.  Atypical neuroleptics: a new approach in the treatment of negative symptoms , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[15]  A. Avenoso,et al.  Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone , 1999, Psychopharmacology.

[16]  C. Beasley,et al.  Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.

[17]  S. Stahl.  Antipsychotic polypharmacy, part 2: tips on use and misuse. , 1999, The Journal of clinical psychiatry.

[18]  S. Stahl,et al.  Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? , 1999, The Journal of clinical psychiatry.

[19]  L. Balant,et al.  Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. , 1999, Therapeutic drug monitoring.

[20]  M. Bourin,et al.  Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[21]  S. Marder,et al.  Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat , 1998, Psychopharmacology.

[22]  O. Olesen,et al.  Serum concentrations and side effects in psychiatric patients during risperidone therapy. , 1998, Therapeutic drug monitoring.

[23]  J. Darby,et al.  Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. , 1997, Journal of clinical psychopharmacology.

[24]  C. Beasley,et al.  Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. , 1997, Journal of clinical psychopharmacology.

[25]  J. de Leon,et al.  Risperidone and cytochrome P450 3A. , 1997, The Journal of clinical psychiatry.

[26]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[27]  A. Peer,et al.  Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man , 1995, Psychopharmacology.

[28]  L. Balant,et al.  Therapeutic Drug Monitoring , 1995 .

[29]  J. Peuskens,et al.  Risperidone in the treatment of negative symptoms of schizophrenia: a meta‐analysis , 1995, International clinical psychopharmacology.

[30]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[31]  R. Conley,et al.  Patient response and resource management: another view of clozapine treatment of schizophrenia. , 1995, The American journal of psychiatry.

[32]  L. Ereshefsky.  Treatment Strategies for Schizophrenia , 1995 .

[33]  J. Richardson,et al.  A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5‐HT2 and dopamine D2 receptors , 1995, International clinical psychopharmacology.

[34]  J. Lieberman,et al.  Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. , 1995, The American journal of psychiatry.

[35]  A. Fitton,et al.  Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. , 1994, Drugs.

[36]  S. Marder,et al.  Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.

[37]  N. Yamaguchi,et al.  In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol , 1994, Pharmacology Biochemistry and Behavior.

[38]  R. Hales,et al.  Pharmacologic approach to management of agitation associated with dementia. , 1994, The Journal of clinical psychiatry.

[39]  B. Cohen,et al.  Tissue Concentrations of Clozapine and its Metabolites in the Rat , 1993, Neuropsychopharmacology.

[40]  M. Eichelbaum,et al.  Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. , 1991, DNA and cell biology.

[41]  R. Cadoret,et al.  Dr. Perry and Associates Reply , 1991 .

[42]  R. Cadoret,et al.  Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. , 1991, The American journal of psychiatry.

[43]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[44]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[45]  U. Gundert-Remy,et al.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations , 2004, European Journal of Clinical Pharmacology.

[46]  E. Perucca,et al.  Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia , 2000, Psychopharmacology.

[47]  E. Perucca,et al.  Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics , 2000, Psychopharmacology.

[48]  W S Fenton,et al.  Determinants of medication compliance in schizophrenia: empirical and clinical findings. , 1997, Schizophrenia bulletin.

[49]  E. Snoeck,et al.  The pharmacokinetics of risperidone in humans: a summary. , 1994, The Journal of clinical psychiatry.

[50]  S. Marder,et al.  Psychopharmacologic treatment of schizophrenia. , 1993, Schizophrenia bulletin.

[51]  H. Meltzer.  Treatment of the neuroleptic-nonresponsive schizophrenic patient. , 1992, Schizophrenia bulletin.

[52]  G. Keepers,et al.  Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. , 1991, The American journal of psychiatry.